Table 2 Clinicopathological characteristic of the patients (serum cohort).
From: Fibrinogen alpha and beta chains as non-invasive predictors of hepatocellular carcinoma progression
Variable | Total cohort (n = 255) | |||
|---|---|---|---|---|
§§N (n = 30) | ¶¶CH (n = 34) | †††LC (n = 33) | ‡‡‡HCC (n = 158) | |
Age (years), mean ± SD | 34.6 ± 7.4 | 46.5 ± 10.5 | 53.1 ± 10.3 | 55.8 ± 9.4 |
Male sex, n (%) | 4 (13.3) | 20 (58.8) | 20 (60.6) | 130 (82.3) |
Etiology, n (%) | ||||
†HBV | 145 (91.8) | |||
v‡HCV | 11 (7.0) | |||
Alcohol | 2 (1.3) | |||
§AST, IU/mL | 16.6 ± 3.7 | 54.3 ± 48.3 | 80.7 ± 97.6 | 54.2 ± 61.6 |
¶ALT, IU/mL | 13.7 ± 7.6 | 65.7 ± 71.8 | 77.0 ± 97.9 | 41.4 ± 37.7 |
Platelet, × 103/µL | 294.7 ± 33.2 | 175.2 ± 51.2 | 129.4 ± 76.5 | 161.8 ± 73.1 |
††AFP (ng/mL), mean ± SD | 26.4 ± 31.9 | 65.8 ± 130.9 | 2632.3 ± 10815.3 | |
Albumin (g/dL), mean ± SD | 4.4 ± 0.9 | 4.0 ± 0.5 | 4.3 ± 0.5 | |
Total Bilirubin (mg/dL), mean ± SD | 0.8 ± 0.3 | 1.1 ± 1.0 | 0.9 ± 2.4 | |
‡‡INR, mean ± SD | 0.4 ± 0.6 | 1.0 ± 0.5 | 1.1 ± 0.1 | |
Modified UICC stage, n (%) | ||||
I | 48 (30.4) | |||
II | 79 (50) | |||
III | 18 (11.4) | |||
IVA | 10 (6.3) | |||
IVB | 3 (1.9) | |||
Vascular invasion, n (%) | 38 (24.0) | |||
Recur, n (%) | 72 (45.6) | |||
